Fibrates therapy: Rational use fenofibrate 2016. Executive summary

Angel Brea; Jesús Millán; Juan F. Ascaso; Mariano Blasco; Angel Díaz; Pedro González-Santos; Antonio Hernández-Mijares; Teresa Mantilla; Juan C. Pedro-Botet; Xavier Pintó

doi:10.1016/j.arteri.2016.06.001

Fibrates therapy: Rational use fenofibrate 2016. Executive summary

Angel Brea, Jesús Millán, Juan F. Ascaso, Mariano Blasco, Angel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Juan C. Pedro-Botet, Xavier Pintó

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

Abstract

© 2016 Sociedad Española de Arteriosclerosis To control lipid factors risk, beyond proper management of LDL cholesterol according to individual risk, detection and treatment of atherogenic dyslipidemia and abnormal levels of triglycerides or HDL cholesterol it should be considered for address a global cardiovascular protection, both in primary and secondary prevention. In this sense, these recommendations collect data on efficacy and safety about the combination statin with fibrates, often necessary for total control of dyslipidemia, particularly in patients with metabolic disorders such as diabetes mellitus, metabolic syndrome or visceral obesity. Reference to control and monitoring of treatment is also done, as well as benefits of fenofibrate not linked directly to their lipid-lowering effect.

Original language	English
Pages (from-to)	295-301
Journal	Clinica e Investigacion en Arteriosclerosis
Volume	28
Issue number	6
DOIs	https://doi.org/10.1016/j.arteri.2016.06.001
Publication status	Published - 1 Nov 2016

Keywords

Atherogenic dyslipidemia
Cardiovascular risk
Fenofibrate
Fibrates
Triglycerides

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.arteri.2016.06.001

Cite this

@article{bc58ccb4eec84c31a59d43d7c545e8d9,

title = "Fibrates therapy: Rational use fenofibrate 2016. Executive summary",

abstract = "{\textcopyright} 2016 Sociedad Espa{\~n}ola de Arteriosclerosis To control lipid factors risk, beyond proper management of LDL cholesterol according to individual risk, detection and treatment of atherogenic dyslipidemia and abnormal levels of triglycerides or HDL cholesterol it should be considered for address a global cardiovascular protection, both in primary and secondary prevention. In this sense, these recommendations collect data on efficacy and safety about the combination statin with fibrates, often necessary for total control of dyslipidemia, particularly in patients with metabolic disorders such as diabetes mellitus, metabolic syndrome or visceral obesity. Reference to control and monitoring of treatment is also done, as well as benefits of fenofibrate not linked directly to their lipid-lowering effect.",

keywords = "Atherogenic dyslipidemia, Cardiovascular risk, Fenofibrate, Fibrates, Triglycerides",

author = "Angel Brea and Jes{\'u}s Mill{\'a}n and Ascaso, {Juan F.} and Mariano Blasco and Angel D{\'i}az and Pedro Gonz{\'a}lez-Santos and Antonio Hern{\'a}ndez-Mijares and Teresa Mantilla and Pedro-Botet, {Juan C.} and Xavier Pint{\'o}",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.arteri.2016.06.001",

language = "English",

volume = "28",

pages = "295--301",

journal = "Cl{\'i}nica e investigaci{\'o}n en arteriosclerosis",

issn = "0214-9168",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Fibrates therapy: Rational use fenofibrate 2016. Executive summary

AU - Brea, Angel

AU - Millán, Jesús

AU - Ascaso, Juan F.

AU - Blasco, Mariano

AU - Díaz, Angel

AU - González-Santos, Pedro

AU - Hernández-Mijares, Antonio

AU - Mantilla, Teresa

AU - Pedro-Botet, Juan C.

AU - Pintó, Xavier

PY - 2016/11/1

Y1 - 2016/11/1

N2 - © 2016 Sociedad Española de Arteriosclerosis To control lipid factors risk, beyond proper management of LDL cholesterol according to individual risk, detection and treatment of atherogenic dyslipidemia and abnormal levels of triglycerides or HDL cholesterol it should be considered for address a global cardiovascular protection, both in primary and secondary prevention. In this sense, these recommendations collect data on efficacy and safety about the combination statin with fibrates, often necessary for total control of dyslipidemia, particularly in patients with metabolic disorders such as diabetes mellitus, metabolic syndrome or visceral obesity. Reference to control and monitoring of treatment is also done, as well as benefits of fenofibrate not linked directly to their lipid-lowering effect.

AB - © 2016 Sociedad Española de Arteriosclerosis To control lipid factors risk, beyond proper management of LDL cholesterol according to individual risk, detection and treatment of atherogenic dyslipidemia and abnormal levels of triglycerides or HDL cholesterol it should be considered for address a global cardiovascular protection, both in primary and secondary prevention. In this sense, these recommendations collect data on efficacy and safety about the combination statin with fibrates, often necessary for total control of dyslipidemia, particularly in patients with metabolic disorders such as diabetes mellitus, metabolic syndrome or visceral obesity. Reference to control and monitoring of treatment is also done, as well as benefits of fenofibrate not linked directly to their lipid-lowering effect.

KW - Atherogenic dyslipidemia

KW - Cardiovascular risk

KW - Fenofibrate

KW - Fibrates

KW - Triglycerides

U2 - 10.1016/j.arteri.2016.06.001

DO - 10.1016/j.arteri.2016.06.001

M3 - Article

SN - 0214-9168

VL - 28

SP - 295

EP - 301

JO - Clínica e investigación en arteriosclerosis

JF - Clínica e investigación en arteriosclerosis

IS - 6

ER -

Fibrates therapy: Rational use fenofibrate 2016. Executive summary

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this